FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2083276084> ?p ?o ?g. }

• W2083276084 endingPage "161" @default.
• W2083276084 startingPage "148" @default.
• W2083276084 abstract "The aim of this article is to evaluate the safety and efficacy of perimenstrual telcagepant, a CGRP receptor antagonist, for headache prophylaxis.We conducted a randomized, double-blind, placebo-controlled, six-month trial in women with migraine for ≥ 3 months who experienced perimenstrual headaches. Women were randomized to telcagepant 140 mg or placebo (2:1 ratio) for seven consecutive days perimenstrually. Safety was assessed by adverse events and laboratory tests. The primary efficacy endpoint was mean monthly headache days in the subset of women reporting perimenstrual migraine (-2 days to +3 days of menses onset) and ≥ 5 moderate or severe migraines per month prior to entering the trial.Telcagepant was generally well tolerated: 66/2660 (2.5%) on telcagepant and 36/1326 (2.7%) on placebo discontinued because of a clinical adverse event. The percentages of patients with clinical adverse events, laboratory adverse events, or discontinuation because of a laboratory adverse event were also similar between treatments. Alanine aminotransferase elevations ≥ 3x normal occurred in 0.6% of women on telcagepant and 0.4% on placebo. Three women on telcagepant vs none on placebo had alanine aminotransferase elevations ≥ 8× normal. In the efficacy subset there was no significant effect of telcagepant (n = 887) vs placebo (n = 447) in mean monthly headache days (treatment difference -0.5 day (95% CI: -1.1, 0.1)). However, telcagepant was associated with a reduction in on-drug headache days (treatment difference -0.4 day (95% CI: -0.5, -0.2), nominal p < 0.001).Telcagepant 140 mg taken perimenstrually for seven days was generally well tolerated, but was associated with transaminase elevations. Telcagepant did not reduce monthly headache frequency, but did reduce perimenstrual headaches." @default.
• W2083276084 created "2016-06-24" @default.
• W2083276084 creator A5001777435 @default.
• W2083276084 creator A5002309452 @default.
• W2083276084 creator A5005299494 @default.
• W2083276084 creator A5009200166 @default.
• W2083276084 creator A5020644806 @default.
• W2083276084 creator A5021135644 @default.
• W2083276084 creator A5039941295 @default.
• W2083276084 creator A5050461006 @default.
• W2083276084 creator A5064619641 @default.
• W2083276084 creator A5074447840 @default.
• W2083276084 creator A5085576539 @default.
• W2083276084 creator A5087230348 @default.
• W2083276084 date "2015-04-29" @default.
• W2083276084 modified "2023-10-01" @default.
• W2083276084 title "Randomized controlled trial of the CGRP receptor antagonist telcagepant for prevention of headache in women with perimenstrual migraine" @default.
• W2083276084 cites W1973511428 @default.
• W2083276084 cites W1973662774 @default.
• W2083276084 cites W2038399206 @default.
• W2083276084 cites W2040853447 @default.
• W2083276084 cites W2044177786 @default.
• W2083276084 cites W2048001053 @default.
• W2083276084 cites W2048132386 @default.
• W2083276084 cites W2055541495 @default.
• W2083276084 cites W2062526596 @default.
• W2083276084 cites W2062955354 @default.
• W2083276084 cites W2070760046 @default.
• W2083276084 cites W2089769968 @default.
• W2083276084 cites W2098988727 @default.
• W2083276084 cites W2122780963 @default.
• W2083276084 cites W2123675905 @default.
• W2083276084 cites W2135858080 @default.
• W2083276084 cites W2137924809 @default.
• W2083276084 cites W2140665207 @default.
• W2083276084 cites W2168280303 @default.
• W2083276084 doi "https://doi.org/10.1177/0333102415584308" @default.
• W2083276084 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/25926620" @default.
• W2083276084 hasPublicationYear "2015" @default.
• W2083276084 type Work @default.
• W2083276084 sameAs 2083276084 @default.
• W2083276084 citedByCount "79" @default.
• W2083276084 countsByYear W20832760842015 @default.
• W2083276084 countsByYear W20832760842016 @default.
• W2083276084 countsByYear W20832760842017 @default.
• W2083276084 countsByYear W20832760842018 @default.
• W2083276084 countsByYear W20832760842019 @default.
• W2083276084 countsByYear W20832760842020 @default.
• W2083276084 countsByYear W20832760842021 @default.
• W2083276084 countsByYear W20832760842022 @default.
• W2083276084 countsByYear W20832760842023 @default.
• W2083276084 crossrefType "journal-article" @default.
• W2083276084 hasAuthorship W2083276084A5001777435 @default.
• W2083276084 hasAuthorship W2083276084A5002309452 @default.
• W2083276084 hasAuthorship W2083276084A5005299494 @default.
• W2083276084 hasAuthorship W2083276084A5009200166 @default.
• W2083276084 hasAuthorship W2083276084A5020644806 @default.
• W2083276084 hasAuthorship W2083276084A5021135644 @default.
• W2083276084 hasAuthorship W2083276084A5039941295 @default.
• W2083276084 hasAuthorship W2083276084A5050461006 @default.
• W2083276084 hasAuthorship W2083276084A5064619641 @default.
• W2083276084 hasAuthorship W2083276084A5074447840 @default.
• W2083276084 hasAuthorship W2083276084A5085576539 @default.
• W2083276084 hasAuthorship W2083276084A5087230348 @default.
• W2083276084 hasBestOaLocation W20832760841 @default.
• W2083276084 hasConcept C126322002 @default.
• W2083276084 hasConcept C141071460 @default.
• W2083276084 hasConcept C142724271 @default.
• W2083276084 hasConcept C168563851 @default.
• W2083276084 hasConcept C197934379 @default.
• W2083276084 hasConcept C204787440 @default.
• W2083276084 hasConcept C27081682 @default.
• W2083276084 hasConcept C2778541695 @default.
• W2083276084 hasConcept C2778715236 @default.
• W2083276084 hasConcept C2780966972 @default.
• W2083276084 hasConcept C42219234 @default.
• W2083276084 hasConcept C71924100 @default.
• W2083276084 hasConceptScore W2083276084C126322002 @default.
• W2083276084 hasConceptScore W2083276084C141071460 @default.
• W2083276084 hasConceptScore W2083276084C142724271 @default.
• W2083276084 hasConceptScore W2083276084C168563851 @default.
• W2083276084 hasConceptScore W2083276084C197934379 @default.
• W2083276084 hasConceptScore W2083276084C204787440 @default.
• W2083276084 hasConceptScore W2083276084C27081682 @default.
• W2083276084 hasConceptScore W2083276084C2778541695 @default.
• W2083276084 hasConceptScore W2083276084C2778715236 @default.
• W2083276084 hasConceptScore W2083276084C2780966972 @default.
• W2083276084 hasConceptScore W2083276084C42219234 @default.
• W2083276084 hasConceptScore W2083276084C71924100 @default.
• W2083276084 hasIssue "2" @default.
• W2083276084 hasLocation W20832760841 @default.
• W2083276084 hasLocation W20832760842 @default.
• W2083276084 hasOpenAccess W2083276084 @default.
• W2083276084 hasPrimaryLocation W20832760841 @default.
• W2083276084 hasRelatedWork W1983582960 @default.
• W2083276084 hasRelatedWork W2010448526 @default.
• W2083276084 hasRelatedWork W2026058186 @default.
• W2083276084 hasRelatedWork W2084581926 @default.

• next